Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines

Christopher S. Burgey, Kyle A. Robinson, Terry A. Lyle, Philip E.J. Sanderson, S. Dale Lewis, Bobby J. Lucas, Julie A. Krueger, Rominder Singh, Cynthia Miller-Stein, Rebecca B. White, Bradley Wong, Elizabeth A. Lyle, Peter D. Williams, Craig A. Coburn, Bruce D. Dorsey, James C. Barrow, Maria T. Stranieri, Marie A. Holahan, Gary R. Sitko, Jacquelynn J. CookDaniel R. McMasters, Colleen M. McDonough, William M. Sanders, Audrey A. Wallace, Franklin C. Clayton, Dennis Bohn, Yvonne M. Leonard, Theodore J. Detwiler, Joseph J. Lynch, Youwei Yan, Zhongguo Chen, Lawrence Kuo, Stephen J. Gardell, Jules A. Shafer, Joseph P. Vacca

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences